Abiomed
American medical device company specializing in heart pumps

Abiomed is an American medical device company that specializes in the development and manufacture of heart pumps. The company is known for its Impella heart pump technology, which is used to support patients with severe heart conditions. Abiomed is headquartered in Danvers, Massachusetts.
History[edit]
Abiomed was founded in 1981 by Dr. David M. Lederman. The company initially focused on developing artificial hearts and circulatory support devices. Over the years, Abiomed has evolved to become a leader in the field of percutaneous heart pumps.
Products[edit]
Abiomed's primary product line is the Impella series of heart pumps. These devices are designed to provide temporary support to the heart, allowing it to rest and recover. The Impella pumps are inserted percutaneously and can be used in various clinical settings, including during high-risk percutaneous coronary intervention (PCI) and in cases of cardiogenic shock.
Impella Heart Pumps[edit]
The Impella heart pumps are small, catheter-based devices that are inserted through the femoral artery and positioned in the left ventricle. They work by drawing blood from the left ventricle and expelling it into the ascending aorta, thereby reducing the workload on the heart and improving cardiac output.
Research and Development[edit]
Abiomed invests heavily in research and development to advance its heart pump technology. The company collaborates with leading medical institutions and participates in clinical trials to expand the indications for its devices and improve patient outcomes.
Corporate Structure[edit]
Abiomed is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol ABMD. The company has a global presence, with offices and facilities in several countries.
Impact on Cardiology[edit]
Abiomed's heart pump technology has had a significant impact on the field of cardiology. The Impella devices have been shown to improve survival rates in patients with severe heart conditions and have become an essential tool in the management of acute heart failure.
Related pages[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian